Your browser doesn't support javascript.
loading
Patient-reported symptoms and burden of eosinophilic esophagitis: evidence from real-world clinical practice.
Xu, Xiao; Kwiatek, Justin; Siddall, James; Genofre, Eduardo; Stirnadel-Farrant, Heide; Katial, Rohit.
Affiliation
  • Xu X; BioPharmaceuticals Market Access and Pricing, AstraZeneca, 200 Orchard Ridge Dr, Gaithersburg, MD, 20878, USA. Xiao.Xu1@astrazeneca.com.
  • Kwiatek J; BioPharmaceuticals Medical, AstraZeneca, 200 Orchard Ridge Dr, Gaithersburg, MD, 20878, USA. Xiao.Xu1@astrazeneca.com.
  • Siddall J; BioPharmaceuticals Medical, AstraZeneca, 200 Orchard Ridge Dr, Gaithersburg, MD, 20878, USA.
  • Genofre E; Adelphi Real World, Bollington, Cheshire, UK.
  • Stirnadel-Farrant H; BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.
  • Katial R; BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
BMC Gastroenterol ; 24(1): 246, 2024 Aug 03.
Article in En | MEDLINE | ID: mdl-39097693
ABSTRACT

BACKGROUND:

Eosinophilic esophagitis is a chronic inflammatory disorder of the esophagus. This real-world study used patient and physician surveys to describe the clinical characteristics and disease burden of eosinophilic esophagitis-overall and in a subgroup of patients with dysphagia despite treatment.

METHODS:

Data analyzed in this study were collected in 2020 from US and EU patients with eosinophilic esophagitis. Eligible patients were aged ≥ 12 years with a diagnosis of eosinophilic esophagitis, had an esophageal count of ≥ 15 eosinophils/high-power field at diagnosis, and were currently prescribed treatment for eosinophilic esophagitis.

RESULTS:

Overall, 1001 patients were included, of whom 356 (36%) had dysphagia despite treatment. Demographics and clinical characteristics were similar in both populations. The severity of eosinophilic esophagitis was mild in more patients overall (69%) versus those with dysphagia despite treatment (48%). Patient disease history was similar in both populations, with some exceptions common patient-reported symptoms were dysphagia (70% and 86%) and heartburn/acid reflux (55% and 49%), and common physician-reported symptoms were dysphagia (75% and 91%) and food impaction (46% and 52%). Treatment history was similar in both populations; overall, the most common treatments were proton pump inhibitors (83%) and topical corticosteroids (51%). Patients reported slightly more days with symptoms, higher impacts on activities of daily living, and slightly higher anxiety or depression in the dysphagia-despite-treatment population versus the overall population.

CONCLUSIONS:

Eosinophilic esophagitis presents severe symptoms and comorbidities that substantially impact patients' well-being and quality of life. Greater awareness of and novel treatments for eosinophilic esophagitis are needed.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Deglutition Disorders / Cost of Illness / Proton Pump Inhibitors / Eosinophilic Esophagitis / Patient Reported Outcome Measures Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: BMC Gastroenterol Journal subject: GASTROENTEROLOGIA Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Deglutition Disorders / Cost of Illness / Proton Pump Inhibitors / Eosinophilic Esophagitis / Patient Reported Outcome Measures Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: BMC Gastroenterol Journal subject: GASTROENTEROLOGIA Year: 2024 Type: Article Affiliation country: United States